AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers.
Hassan Lemjabbar-Alaoui, Csaba J Peto, Yi-Wei Yang...
https://pubmed.ncbi.nlm.nih.gov/32905466/Actively Recruiting
Led by AtlasMedx, Incorporated · Updated on 2025-05-01
122
Participants Needed
4
Research Sites
8 weeks
Total Duration
Researchers are evaluating AMXI-5001, an oral drug that blocks PARP and microtubule polymerization, in adults with advanced cancers that have not responded to other treatments. This Phase III trial aims first to find the best dose and then to study the drugs safety and effects in more detail. The study includes participants with several types of advanced cancers, including breast, ovarian, prostate, pancreatic, and other malignant tumors. The trial has two parts Phase I involves dose escalation, where up to 70 participants receive AMXI-5001 orally twice a day with food on a weekly continuous 7-day schedule, with each treatment cycle lasting 28 days. After determining the recommended dose, Phase II will enroll up to 52 participants to further assess safety, drug levels in the blood, and anti-tumor activity using the chosen dose. All participants receive the study drug as monotherapy. Participants will be monitored for safety, drug concentration in plasma, and tumor response using standard imaging and laboratory tests over approximately 24 months. The primary goals include finding the maximum tolerated dose and recommended dose for Phase II, as well as characterizing the safety profile. Participants must consent and meet eligibility criteria related to their cancer status and overall health. The trial will continue until about October 2026.
CONDITIONS
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
B
Bonnie Wettersten, MS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
AtlasMedx, Incorporated
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | AMXI-5001 (Investigational) | Systemic Therapy (Guideline-Recommended Current Care) |
|---|---|---|
| What it is | AMXI-5001 is an oral investigational drug that inhibits PARP1/2 and microtubule polymerization, under clinical evaluation for advanced cancers that have progressed despite or are intolerant to standard therapies. | Systemic therapy options include guideline-recommended chemotherapy, endocrine, or targeted agents (such as endocrine therapy, PARP inhibitors, platinum-based regimens, or taxanes), selected based on cancer type and previous treatments for advanced or metastatic disease. |
| Role in study | Assigned to all eligible participants as the only study treatment in this phase I/II trial. | Represents the recommended care options for similar patients outside the trial who have progressed through or are intolerant to standard therapies. |
| Primary use | Being studied for its safety, maximum tolerated dose, and recommended phase II dose, as well as early signals of anti-tumor activity in advanced solid tumors. | Used for disease control, symptom management, and prolonging survival in advanced or metastatic cancer following progression on, or intolerance to, initial standard treatments. |
| How it is given or performed | AMXI-5001 is administered orally twice daily with food, on a continuous 7-day schedule per 28-day cycle. Initial dosing is escalated to identify an appropriate phase II dose. | Systemic therapies are given intravenously or orally, depending on agent (e.g., chemotherapy, endocrine therapy, PARP inhibitors, taxanes), with dosage and schedule based on the patient's disease and prior treatments. |
| Evidence and maturity | Evidence for AMXI-5001 in human patients is currently limited to ongoing phase I/II clinical trial investigation; published clinical efficacy and safety outcomes are not yet available. | The efficacy and safety of guideline-recommended systemic therapies are supported by multiple randomized clinical trials and confirmed in authoritative practice guidelines for post-progression/metastatic advanced solid tumor care. |
| Important limitations | As this is an early-phase single-arm study, AMXI-5001’s long-term efficacy, comparative effectiveness, and safety are unc ertain; assessment is ongoing, and results are not yet available. | Response rates and benefit with current systemic therapies after progression on standard regimens are often limited, and options depend on individual tumor biology and prior treatment history. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to approximately 24 months
Participants receive oral AMXI-5001 twice daily as monotherapy in 28-day continuous cycles to treat advanced malignancies.
Weekly visits for treatment and assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Hassan Lemjabbar-Alaoui, Csaba J Peto, Yi-Wei Yang...
https://pubmed.ncbi.nlm.nih.gov/32905466/AtlasMedx, Incorporated
Lead Sponsor